Principal Financial Group
CTIC

Principal Financial Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Principal Financial Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,244
Closed -$127K – 2559
2023
Q1 		$127K Buy
30,244
+2,346
+8% +$12.2K ﹤0.01% 2262
2022
Q4 		$168K Buy
27,898
+5,898
+27% +$32.2K ﹤0.01% 2227
2022
Q3 		$128K Buy
22,000
+4,556
+26% +$28.4K ﹤0.01% 2285
2022
Q2 		$104K Buy
+17,444
New +$89.3K ﹤0.01% 2387
2018
Q4 		– Sell
-10,835
Closed -$23K – 2407
2018
Q3 		$23K Buy
+10,835
New +$26.8K ﹤0.01% 2287
2016
Q2 		– Sell
-4,032
Closed -$21K – 2265
2016
Q1 		$21K Buy
4,032
+1,051
+35% +$8.4K ﹤0.01% 2157
2015
Q4 		$37K Buy
2,981
+197
+7% +$2.63K ﹤0.01% 2168
2015
Q3 		$41K Buy
+2,784
New +$48.1K ﹤0.01% 2150
2015
Q2 		– Sell
-4,450
Closed -$81K – 2287
2015
Q1 		$81K Buy
4,450
+669
+18% +$15.1K ﹤0.01% 2122
2014
Q4 		$89K Sell
3,781
-664
-15% -$15.4K ﹤0.01% 2122
2014
Q3 		$108K Hold
4,445
– – ﹤0.01% 2134
2014
Q2 		$125K Sell
4,445
-2,108
-32% -$63.3K ﹤0.01% 2180
2014
Q1 		$223K Buy
+6,553
New +$224K ﹤0.01% 2100

Other funds holding CTIC

UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Principal Financial Group's CTIC Position: Q2 2023 in Review

Principal Financial Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 30,244 shares — an estimated $127K sold.

Principal Financial Group first reported a position in CTIC in Q1 2014 and held it in 13 quarters. The position peaked at $223K in Q1 2014. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

  • Principal Financial Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
  • Principal Financial Group sold 30,244 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $127K.
  • Principal Financial Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 13 quarters.
  • Principal Financial Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $223K in Q1 2014.
  • 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Principal Financial Group's 13F filing for Q2 2023, filed 7 Aug 2023.